ストックスクリーナーアプリを入手
54.68
2.44%
-1.37
アフターアワーズ：
55.00
0.32
+0.59%
Biomarin Pharmaceutical Inc (BMRN) 最新ニュース
Raymond James upgrades BioMarin stock to strong buy on valuation - Investing.com
Why is BioMarin Pharmaceutical stock gaining today? By Investing.com - Investing.com Canada
Raymond James upgrades BioMarin stock to strong buy on valuation By Investing.com - Investing.com South Africa
Bank of America Securities Sticks to Its Buy Rating for BioMarin Pharmaceutical (BMRN) - The Globe and Mail
RBC Capital Keeps Their Hold Rating on BioMarin Pharmaceutical (BMRN) - The Globe and Mail
BioMarin to present data on achondroplasia treatment at ASBMR - Investing.com
New imaging data examine a growth drug's effect on a skull area linked to serious complications in children. - Stock Titan
BioMarin Pharmaceutical (BMRN), What Is Behind The Latest Attention? - Yahoo Finance
Analysts Conflicted on These Healthcare Names: Rocket Pharmaceuticals (RCKT) and BioMarin Pharmaceutical (BMRN) - The Globe and Mail
BioMarin Pharmaceutical Inc. (BMRN) Stock Forecasts - Yahoo Finance
FDA Grants Priority Review to BridgeBio's Dwarfism Drug Filing - Zacks Investment Research
RBC Capital lowers BioMarin price target to $62 - scanx.trade
Citigroup raises BioMarin price target to $76 - scanx.trade
BioMarin names Cara Bauer as chief people officer - Investing.com
BioMarin Appoints Cara Bauer as Chief People Officer - PR Newswire
BioMarin presents five-year data on Pompe disease treatment - Investing.com
BioMarin presents five-year data on Pompe disease treatment By Investing.com - Investing.com Canada
BioMarin Announces Five-Year Phase 3 Data for POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) at World Muscle Society Annual Congress - PR Newswire
BioMarin Pharmaceutical (NasdaqGS:BMRN) Stock Forecast & Analyst Predictions - Simply Wall Street
BioMarin Pharmaceutical Inc. (BMRN) Stock Forecasts - Yahoo! Finance Canada
Profluent and BioMarin Partner to Design Novel Enzyme Therapies Using AI - HLTH
After 4,086 shares were delivered or withheld, BioMarin (BMRN) R&D chief holds 47,732 shares. - Stock Titan
The Strategic Financial Case for BioMarin Pharmaceutical (BMRN) - Yahoo Finance
BioMarin and Profluent partner on AI-designed enzyme therapies - Pharmaceutical Technology
Major North Bay biotech employer to cut 119 jobs in consolidation move - The Press Democrat
Biomarin Pharmaceutical Enters Settlement And License Agreement With Ascendis Pharma On Sept 24, 2026 - TradingView
BioMarin Licenses CNP IP to Ascendis; 20% US, 18% EU/Brazil/S. Korea Royalties Until May 2030 - TradingView
Profluent And BioMarin Pharmaceutical Inc. Partner To Design Novel Medicines Using AI - marketscreener.com
Profluent Partners With BioMarin to Design Novel Medicines Using AI - Yahoo Finance
BioMarin Pharmaceutical Inc. (BMRN) Stock forecasts - au.finance.yahoo.com
Enzyme Replacement Therapy Market to Grow to USD 27.90 Billion by 2035 at a CAGR of 8.59%SNS Insider - GlobeNewswire Inc.
BioMarin Pharmaceutical Inc. (BMRN) Stock Price, News, Quote & History - Yahoo! Finance Canada
BioMarin Pharmaceutical Inc. (BMRN) stock price, news, quote and history - Yahoo Finance UK
BioMarin Pharmaceutical Inc. (BMRN) stock price, news, quote and history - Yahoo Finance Singapore
BioMarin Pharmaceutical Inc. (BMRN) Latest Stock News & Headlines - Yahoo Finance
BioMarin: Why I See Significant Upside Into 2027 (NASDAQ:BMRN) - Seeking Alpha
BioMarin Pharmaceutical Inc. (BMRN): Stock Analysis Reveals 43% Potential Upside - DirectorsTalk Interviews
What Is Drawing Fresh Attention To BioMarin Pharmaceutical (BMRN)? - Yahoo Finance
Did VOXZOGO’s Hypochondroplasia Win and New R&D Hire Just Reframe BioMarin’s (BMRN) Investment Narrative? - Yahoo Finance
BioMarin Targets Amicus Synergies as VOXZOGO Nears $1B Milestone - Yahoo Finance
BioMarin Stops Voxzogo Development for Noonan Syndrome - Yahoo Finance
BioMarin (NASDAQ: BMRN) director awarded 6,140 stock units - Stock Titan
BioMarin Announces Appointment of Robert Plenge, M.D., Ph.D., Chief Research Officer of Bristol Myers Squibb, to Board of Directors - PR Newswire
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Appoints BMS R&D Chief Robert Plenge to Board - TradingView
BioMarin Shares Jump 5% After Global Patent Settlement With Ascendis - Yahoo Finance
BioMarin at Citi summit: voxzogo drives growth as pipeline widens - Investing.com
BMRN: Blockbuster growth, pipeline innovation, and AI-driven efficiencies drive future outlook - TradingView
BioMarin at Citi summit: voxzogo drives growth as pipeline widens - Investing.com India
BMRN: Portfolio expansion, robust growth, and pipeline innovation drive long-term outlook - TradingView
BioMarin at Cantor conference: growth plan widens beyond Voxzogo By Investing.com - Investing.com Canada
2.19%
0.07%
大文字化:
|
ボリューム (24 時間):